SUTENT (sunitinib) for Gastrointestinal Stromal Tumor, Renal Cell Carcinoma & Pancreatic Neuroendocrine Tumors

1 / 1
Share this content:

This slideshow reviews drug information for SUTENT (sunitinib), indicated for gastrointestinal stromal tumor, advanced renal cell carcinoma & advanced pancreatic neuroendocrine tumors.
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 18: Clinical Safety and Efficacy
Slide 34: Drug Storage and Supply
Slide 36: References

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters